MKMeganathan Kannan

Meganathan Kannan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Meganathan Kannan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Acquired Glanzmann’s thrombasthenia associated with Hairy cell leukaemia

    by M. Kannan, T. Chatterjee, F. Ahmad, R. Kumar, V. P. Choudhry, R. Saxena


  • Pro CR Global: An effective screening test for thrombophilia

    by P.K. Gupta, R. Ahmed, M. Kannan, S.N. Dwivedi, V.P. Choudhry, R. Saxena

    In the present study, the Pro CR Global test was evaluated as a screening test for estimation of the activity of the main plasma components of the anticoagulant protein C (PC) / protein S (PS) pathway; 300 patients with a history of thrombosis were investigated for Pro CR Global. It was positive in 74 patients. Tests for estimation of PC, PS, activated protein C resistance (APCR), and lupus anticoagulant (LAC) were performed in all the patients with abnormal Pro CR Global and in 10 patients with normal Pro CR Global. In all, 66 of the 74 patients had a defect in PC/PS/APCR or LAC; 18 patients had both PC and PS deficiency, 25 had PS deficiency alone, 10 had PC deficiency alone, one had APCR alone, eight had PS, PC deficiency with APCR, and four had PS deficiency with APCR. In the 10 patients who tested negative with the Pro CR Global test, PC, APCR, and LAC were negative in all. However, PS deficiency was seen in two of them. The sensitivity and specificity of Pro CR Global, calculated with respect to positivity of PC, PS, LAC, or APCR as the gold standard, were 97% and 50%, respectively. The diagnostic accuracy of the assay was 88.1%. It is thus recommended that Pro CR Global can be used effectively as a screening test to detect abnormality in the PC/PS/APCR/LAC pathway. Am. J. Hematol. 74:208–210, 2003.


    • 1 October 2003
      • Vol. 46  (4) , 563-4

    Contribution of iron deficiency to anemia in chronic renal failure.

    by Meenal Gupta, M Kannan, Sanjay Gupta, Renu Saxena

    Prevalence of iron deficiency in anemia of chronic renal failure (CRF) has long been the subject of interest, because the patients of CRF with coexistent iron deficiency anemia need to be treated with iron preparations before starting erythropoietin therapy. Prevalence of iron deficiency in CRF is higher in Indian patients as compared to the West. Diagnosis of iron deficiency in patients with CRF is difficult. Bone marrow iron which is considered to be the gold standard is a painful and invasive procedure. In the present study we used serum transferrin receptor and serum ferritin levels, since not much Indian data is available on this.


    • 1 October 2003
      • Vol. 46  (4) , 621-4

    Venous thrombosis: prevalence of prothrombotic defects in north Indian population.

    by Maitreyee Bhattacharyya, M Kannan, V P Chaudhry, Renu Saxena

    431 patients with thrombosis of different venous system were evaluated for underlying acquired and inherited prothrombotic states. Associated acquired risk factors were observed to be present in 28.7% patients and possible inherited in 32.3%, in the rest, no cause could be identified. Major acquired risk factors included coexistence of liver disease (12.2%), oral contraceptives (4.1%), puerperium (2.5%), malignancy (2.3%) and lupus anticoagulant (2%). Low levels of protein C were detected in 21.1% and of which 11.3% were attributed to acquired factors. Protein S deficiency was found in 19.0% and of these 10.4% cases were associated with acquired risk factors. Antithrombin III (AT III) deficiency was detected in 6.4% of patients, of which 4.8% were secondary to acquired factors. In the rest, deficiency of protein C, protein S and AT III were attributed to inherited factors as no associated acquired risk factor was present. Activated protein C resistance (APC-R) was present in 12.5% cases.


  • Does the MTHFR 677T allele alter the clinical phenotype in severe haemophilia A?

    by Rafeeq Ahmed, M. Kannan, Ved Prakash Choudhry, Renu Saxena